Result for
Tag: testing
October 12, 2020
Diagnostic Accuracy of FDA Authorized Serology Tests to Detect SARS-CoV-2 Antibodies A Systematic Review and Meta-Analysis
[Pre-print, not peer reviewed]A systematic review and meta-analysis of the diagnostic accuracy of seven different FDA-authorized tests for SARS-CoV-2 antibodies found that the pooled sensitivity was 87% and the pooled specificity was nearly 100%. Sensitivity increased with increased time between symptom onset and sample collection: at ≤ 7 days, sensitivity was 44%, for 8-14 days,…
October 9, 2020
Differences in Performance Characteristics Among Four High-Throughput Assays for the Detection of Antibodies Against SARS-CoV-2 Using a Common Set of Patient Samples
A study comparing the performance characteristics of four high-throughput assays for SARS-CoV-2 antibody detection indicated that for samples collected from patients 14 or more days after symptom onset, the Roche and Siemens assays had the highest sensitivities (96.6% and 98.3%, respectively) and specificities (100% for both) out of the four tests. The authors note that…
October 8, 2020
Extremely Potent Human Monoclonal Antibodies from Convalescent Covid-19 Patients
[Pre-print, not peer reviewed] Single cell sorting of 4277 SARS-CoV-2 spike protein specific memory B cells from 14 COVID-19 survivors identified 220 neutralizing antibodies that expressed as IgG. Among these, 3 monoclonal antibodies were potent enough to neutralize the wild type and DG14G mutant viruses in vitro at a concentration of <10 ng/mL, indicating they…
October 6, 2020
Adolescent with COVID-19 as the Source of an Outbreak at a 3-Week Family Gathering — Four States, June–July 2020
An adolescent (13 years old) was the index case of an outbreak that occurred during a 3-week family gathering where 11 of 14 attendees developed COVID-19, despite the index case testing negative with a rapid antigen test prior to the gathering. Six other family members who maintained physical distancing by remaining outdoors did not develop…
October 5, 2020
A One-Minute Blood Test to Monitor Immune Responses in COVID-19 Patients and Predict Clinical Risks of Developing Moderate to Severe Symptoms
[Preprint, not peer-reviewed] A nanoparticle-enabled blood test could detect a statistically significant differences in immune response between samples collected from COVID-19 patients with no or mild symptoms (n=38) and those with moderate/severe symptoms (n=115), with results available in <1 minute. The authors conclude this new rapid test may be used as a point-of-care clinical tool…
October 2, 2020
Effectiveness of Tests to Detect the Presence of SARS-CoV-2 Virus, and Antibodies to SARS-CoV-2, to Inform COVID-19 Diagnosis: A Rapid Systematic Review
A rapid systematic review of both SARS-CoV-2 virus and antibody testing found a sensitivity of 87.8% for an initial RT-PCR test, while sensitivity of antibody tests ranged from 18.4% to 96.1% and specificity ranged from 88.9% to 100%. The authors note that estimates of diagnostic accuracy should be interpreted cautiously due to the lack of…
October 1, 2020
Real-Time Screening of Specimen Pools for Coronavirus Disease 2019 (COVID-19) Infection at Sanya Airport, Hainan Island, China
A 10:1 pooled test strategy for nasopharyngeal swabs was used to screen airline passengers arriving in China. Among 944 specimens collected and tested for RNA using the Xpert Xpress assay, the pooled approach identified 2 positive individuals who were immediately quarantined, which resulted in no local contacts in China. The pooled approach saved 827 (87.6%)…
September 30, 2020
Reliability of Serological Tests for COVID-19: Comparison of Three Immunochromatography Test Kits for SARS-CoV-2 Antibodies
Three commercially available serological test kits using immunochromatography (Hangzhou AllTest, SD BIOSENSOR, and Vazyme) were evaluated using identical sample sets consisting of 99 serum samples from SARS-CoV-2 positive patients and 100 serum samples from healthy volunteers in 2017. All test kits achieved >97% specificity for IgM and IgG and >97% sensitivity to IgG at 13…
Comparative Study of Four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) Platforms Demonstrates That ID NOW Performance Is Impaired Substantially by Patient and Specimen Type
The nucleic acid amplification test (NAAT) platform Abbott ID NOW performed significantly worse than similar tests (Abbott m2000, DiaSorine Simplexa, and Cepheid Xpert) in detecting SARS-CoV-2 RNA in a comparative study. All four tests were used in parallel on nasopharyngeal and nasal samples from 88 emergency department and hospital-admitted patients. In particular, the ID NOW…
September 29, 2020
Epidemiological Correlates of PCR Cycle Threshold Values in the Detection of SARS-CoV-2
A study of household transmission from people with mild COVID-19 found that SARS-CoV-2 RNA concentrations were lowest soon after symptoms appeared and increased with time since symptom onset. Viral concentrations were higher in patients under 18 years of age (p=0.01) and those reporting upper respiratory symptoms at the time of sample collection (p=0.001), and were…
Previous page Next page